Weekly Top News – Psoriasis – September 2, 2019

September 2, 2019

Otezla (apremilast) / Amgen
Bristol-Myers Squibb announces agreement between Celgene and Amgen to divest Otezla for $13.4 billion (Businesswire) – Aug 26, 2019 – “Bristol-Myers Squibb Company…announced today that Celgene Corporation…has entered into an agreement with Amgen…under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash….The closing of the acquisition covered by the agreement with Amgen is contingent on Bristol-Myers Squibb and Celgene entering into a consent decree with the Federal Trade Commission (FTC)…’establishing OTEZLA as an important medicine for patients with psoriasis, psoriatic arthritis and Behçet’s Disease’…Bristol-Myers Squibb now expects the pending merger with Celgene to close by the end of 2019.”

 

Otezla (apremilast) / Amgen
Otezla sales projection: $2.2B in FY2020 (CFRA) – Sep 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 67873275; Page no: 1; REPORT TITLE: “Amgen Inc- Otezla deal highly accretive – Provides synergy and accelerates rev/EPS growth”; AUTHOR: Werber, Yaron, et al; DATE: 08/26/2019

 

Otezla (apremilast) / Amgen
Otezla patent expiry: February 2028 (CFRA) – Sep 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 67874668; Page no: 5; REPORT TITLE: “Amgen Inc”; AUTHOR: Huang, Kevin, et al; DATE: 08/26/2019

 

Otezla (apremilast) / Amgen
Otezla WW sales projection: $3.1B (US: $2.5B) peak in 2028 (RBC Capital Markets (Canada)) – Sep 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 67873985; Page no: 3; REPORT TITLE: “Amgen Inc. – Thesis-changing M&A comes at a high cost: Otezla acquisition adds +$14/sh to PT”; AUTHOR: Mackay, Kennen, et al; DATE: 08/26/2019

 

Otezla (apremilast) / Amgen
Otezla sales projection: $2.2B in 2020, $3.1B peak and guidance of $1.9B in 2019 (J.P. Morgan) – Sep 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 67885180; Page no: 1; REPORT TITLE: “Amgen Inc- Amgen Inc: Updating model for Otezla acquisition; It helps but additional levers needed to further boost growth outlook”; AUTHOR: Kasimov, Cory, et al; DATE: 08/28/2019

 

Otezla (apremilast) / Amgen
Otezla: Expiry of patent in US in 2028 (Amgen) – Aug 31, 2019 – Amgen to Acquire Otezla  
[Screenshot]

 

Otezla (apremilast) / Amgen
Otezla sales projection: $3.7B in 2026 (Cantor Fitzgerald) – Sep 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 67873189; Page no: 1; REPORT TITLE: “Amgen Inc- Post Enbrel, Amgen keeps on trucking with a new I&I add to their portfolio”; AUTHOR: Research Department; DATE: 08/26/2019

 

Otezla (apremilast) / Amgen
Otezla sales projection: $1.9B in 2019 and $2.2B in 2020 (Jefferies) – Sep 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 67873157; Page no: 1, 3; REPORT TITLE: “Amgen Inc- Smart deal and very accretive…we’d buy the dip today; Reiterate BUY”; AUTHOR: Yee, Michael, et al; DATE: 08/26/2019

No Comments

Post a Comment

Comment
Name
Email
Website